The pharmaceutical industry or indeed the drug market has historically used a variety of organic substances and resources to create medicine for various applications. Several poisonous plants, for example, have been turned into viable painkillers. Now, scientists are thinking of using one such plant to provide males with an effective birth control method.
Although numerous projects involving the development of birth control pills for men have been in the works, the current proven options that are in the market right now are condoms and a vasectomy. In comparison, women have a whole host of options. In an effort to change this University of Minnesota researchers are looking at a plant called Ouabain, which was used in Africa to stop the hearts of enemies, Futurism reports.
The use of such a method might seem extreme, but there appears to be sound science behind it. The reason why the plant is able to stop hearts is because of protein subunits that essentially short-circuits the organ. Without consistent electrical impulses at the right level, the heart can’t function properly.
Interestingly, this same protein subunit could also cripple sperm cells, making them unable to swim effectively. If the sperm can’t swim very far or fast, they can’t reach egg cells to fertilize them.
In the paper that the researchers published, they posed the potential effectiveness of the poison on humans as was already established in lab mice. The sperm activity of the subjects was basically lowered to levels that rendered them unable to reproduce without any adverse effects on their hearts.
On the other hand, body chemistry of mice and humans are different, so it’s still worth pointing out that more tests are needed. There’s also the matter of the long-term effects that the plant could have as a birth control option since some men might actually want to have children eventually.


FDA Pilot Program Eases Rules for Nicotine Pouch Makers
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Tabletop particle accelerator could transform medicine and materials science
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Neuralink Expands Brain Implant Trials with 12 Global Patients
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 



